SF Healthcare Week: Teva CEO Richard Francis discusses the TL1A space, and the how company's overall focus has transformed to innovation

blonca9
Jan 13
1 min read

He describes how he believes the TL1A compares to others in the field, other programs in the company's innovation pipeline, and the current status of market uptake for biosimilars in Europe and the United States.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

SF Healthcare Week: Teva CEO Richard Francis discusses the TL1A space, and the how company's overall focus has transformed to innovation

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight